

Characteristics of ATP-Induced Current Through P2X₇ Receptor in NG108-15 Cells: Unique Antagonist Sensitivity and Lack of Pore Formation

Tomokazu Watano, Isao Matsuoka and Junko Kimura*

Department of Pharmacology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima 960-1295, Japan

Received November 14, 2001 Accepted January 7, 2002

ABSTRACT—ATP activates the mouse P2X₇ receptor and induces a nonselective-cation current in NG108-15 cells. We investigated the effects of five receptor antagonists on the ATP-induced nonselective-cation current through P2X₇ receptor ($I_{NS-P2X7}$) in NG108-15 cells. Nonselective P2 receptor antagonists, RB-2, PPADS and suramin inhibited the $I_{NS-P2X7}$ with IC_{50} values of 4.3, 53 and 40 μ M, respectively. However, KN-04, which is a potent antagonist of human P2X₇ receptors but is not that of rat P2X₇ receptors, had only a weak blocking effect. Furthermore, oxidized-ATP (300 μ M), an antagonist of the P2X₇ receptor-mediated pore-formation, did not affect the $I_{NS-P2X7}$. Prolonged ATP application did not increase the membrane permeability to large molecules, *N*-methyl-D-glucamine or Yo-Pro-1, indicating that pore-formation was not promoted by the P2X₇ receptor activation in NG108-15 cells. These results suggest that antagonist sensitivities and pore-forming properties of the P2X₇ receptors in NG108-15 cells are different from those of other cells types.

Keywords: ATP, P2X₇ receptor, Antagonist, Pore formation, NG108-15 cell

Extracellular ATP exerts its diverse physiological effects through activation of P2 receptors. P2X receptors are ligand-gated nonselective cation channels and currently seven subtypes (P2X₁₋₇) are known (1, 2). P2X₇ receptors are unique in several respects compared to other P2X receptors (3, 4). First, while other P2X (P2X₁₋₆) receptors are activated by submicromolar concentrations of ATP, the P2X₇ receptor requires much higher concentrations (>0.3 mM) of ATP for activation (5). Second, the effective form of ATP that activates the P2X₇ receptor is the free base of ATP⁴⁻ (6) and thus the ATP-induced nonselective-cation current through P2X₇ receptor ($I_{NS-P2X7}$) is potentiated by reducing external Mg²⁺ (7). Third, benzoylbenzoic ATP (BzATP) is a more potent agonist than ATP (7–9). Fourth, brief stimulation of the P2X₇ receptor opens nonselective cation channels, while sustained or repetitive activation of the P2X₇ receptor results in the formation of large pores (9, 10), which might be the mechanism of the involvement of the P2X₇ receptor in ATP-induced cell death of monocytes and macrophages (11, 12).

NG108-15 cells are hybrids of mouse neuroblastoma N18TG-2 and rat glioma C6Bu-1 cells (13). We previously

found that NG108-15 cells express functional P2X₇ receptors, which are originated from mouse N18TG-2 cells (7, 14). In NG108-15 cells, the P2X₇-receptor agonists BzATP and high concentrations of ATP (>500 μ M) open the P2X₇ receptor-nonselective cation channels, which lead to a Ca²⁺ influx from the extracellular space and sustained increase in intracellular Ca²⁺ concentration (7, 15, 16).

The P2X₇ receptor is inhibited by several compounds, including RB-2, PPADS, suramin (10, 17–19), KN-04 (20, 21) and oxidized-ATP (22, 23). The antagonistic effects of these compounds are different among species and they also vary among cell types even within the same species. For example, KN-04 is a potent antagonist of human P2X₇ receptor (20, 21), but does not antagonize rat P2X₇ receptors (21). In the present study, we investigated the effects of P2 antagonists on the mouse P2X₇ receptor current in NG108-15 cells, using the whole cell voltage clamp. We also investigated whether prolonged application of ATP induces pore formation in NG108-15 cells.

MATERIALS AND METHODS

Cell culture

NG108-15 cells were grown in high-glucose Dulbecco's modified Eagle's medium supplemented with 7% fetal

*Corresponding author. FAX: +81-24-548-0575
E-mail: jkimura@fmu.ac.jp

bovine serum, 100 μ M hypoxanthine, 0.4 μ M aminopterin and 16 μ M thymidine at 37°C in a humidified atmosphere of 10% CO₂ and 90% air (24). For electrophysiological study, cells were seeded in 12-well tissue culture plates at a density of 1×10^5 cell/well and cultured for 2–3 days until becoming confluent. Before experiments, cells were harvested from each well and dispersed in an experimental chamber.

Electrophysiological study

Electrophysiological experiments were carried out using the whole-cell configuration of the patch-clamp technique (25) as described previously (7, 14, 26). Patch pipettes had a tip resistance of about 2 M Ω when filled with an intracellular solution containing 110 mM CsOH, 30 mM CsCl, 50 mM DL-aspartic acid, 5 mM MgATP, 3 mM MgCl₂, 5 mM potassium creatine phosphate, 10 mM EGTA and 20 mM HEPES (adjusted to pH 7.2 with DL-aspartic acid). The cells were dispersed in an experimental chamber perfused with Tyrode solution containing 140 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl₂, 1 mM MgCl₂, 0.33 mM NaH₂PO₄, 5.5 mM glucose and 5 mM HEPES (adjusted to pH 7.4 with NaOH). The temperature of the external solution was maintained at approximately 37°C by a silicon tube water jacket.

Membrane potentials were controlled by a model CEZ-2300 patch-clamp amplifier (Nihon Kohden, Tokyo). Membrane currents were acquired on-line and subsequently analyzed with a computer (DimensionV333C; Dell, Round Rock, TX, USA) using pCLAMP7 software (Axon, Union City, CA, USA). The current-voltage (I-V) relation was obtained by ramp pulses from a holding potential of -10 mV, initially depolarized to 60 mV, then hyperpolarized to -120 mV, and depolarized back to the holding potential with a speed of 1 V/s. The ramp pulse was applied every 3 s.

All the test agents were added to the superfusate. ATP (1 mM) was applied for 10–20 s repetitively with 1-min intervals to induce the I_{NS-P2X7}. Although I_{NS-P2X7} did not run-down significantly, we induced the I_{NS-P2X7} at least twice to confirm that the current magnitudes were similar, and then an antagonist (RB-2, PPADS, suramin or KN-04) was applied. After perfusing the antagonist for 30 s, ATP was added. The effect of an antagonist was expressed as a percent inhibition, which was calculated by dividing the I_{NS-P2X7} magnitude in the presence of an antagonist by that just before introducing the antagonist. Since the inhibition by oxidized-ATP required an incubation period of 120 min (27), the current densities were compared between the cells treated with and those without oxidized-ATP. The current density was obtained by dividing the current by the membrane capacitance (C_m). C_m was calculated using the test protocol in pCLAMP7 software with the following

equation:

$$C_m = i_c dt / dv$$

where i_c is the capacitive current. Data are expressed as means \pm S.E.M. IC₅₀ values are determined by probit analysis using EXCEL software and expressed as geometric means with 95% confidence.

To determine whether pore formation of P2X₇ receptors occurs, the reversal potential of the I_{NS-P2X7} activated by 3 mM ATP was first measured in the Tyrode solution containing 140 mM Na⁺ and then the external solution was changed to one containing 140 mM *N*-methyl-D-glucamine (NMDG) instead of Na⁺. The divalent cation concentrations were the same in both solutions.

Yo-Pro-1 uptake

P2X₇ receptor-mediated pore formation was also evaluated by uptake of Yo-Pro-1, a fluorescence DNA chelating dye (28). Cells resuspended at $1 - 2 \times 10^6$ cells/ml in the HEPES buffer containing 10 μ M Yo-Pro-1 (Molecular Probes, Eugene, OR, USA) were transferred into a 10 \times 10 mm quartz cuvette placed in the thermostat-regulated sample chamber of a dual-excitation beam spectrofluorometer (F-2000; Hitachi, Tokyo). Cells were continuously stirred with a circular stir and stimulated with 1 mM ATP at 37°C. The fluorescence change in Yo-Pro-1-containing cell suspension was continuously monitored with an excitation wavelength of 490 nm, and emission of 509 nm. At the end of the experiments, digitonin (50 μ g/ml) was added to the cell suspension to obtain maximal fluorescence.

Drugs

ATP (adenosine 5'-triphosphate 2Na; Wako, Osaka) and oxidized-ATP (Sigma, St. Louis, MO, USA) were dissolved in water and diluted with Tyrode solution. The pH was adjusted to 7.4 with NaOH. RB-2 (reactive blue 2) (RBI, Natick, MA, USA), PPADS (pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid) (Tocris, Bristol, UK), suramin (RBI), KN-04 ([*N*-1-[*N*-methyl-*p*-(5-isoquinolinesulfonyl)benzyl]-2-(4-phenylpiperazine)ethyl]-5-isoquinolinesulfonamide) (Seikagaku Corporation, Tokyo), KN-62 ([1-[*N,O*-bis(5-isoquinolinesulfonyl)-*N*-methyl-L-tyrosyl]-4-phenylpiperazine]) (Seikagaku Corporation) were dissolved in dimethylsulfoxide (DMSO) and diluted with Tyrode solution. The final concentration of DMSO was less than 0.1%.

RESULTS

Effects of RB-2, PPADS and suramin on I_{NS-P2X7}

We first investigated the effects of the non-selective P2 receptor antagonists, RB-2, PPADS and suramin. RB-2 (3 μ M) did not affect the basal current, but it inhibited the I_{NS-P2X7} induced by 1 mM ATP (Fig. 1A). The inhibition by




Fig. 1. Effect of RB-2 on the $I_{NS-P2X7}$. A: Typical chart recordings (upper panels) and I-V curves (lower panels) of $I_{NS-P2X7}$ before (left), in the presence of (middle) and after washing out (right) RB-2. ATP was applied during the period shown by the horizontal bars. RB-2 ($3 \mu\text{M}$) was applied 30 s before ATP application. B: Difference I-V curves obtained by subtracting the control from the maximal current response to ATP at each trace in A, indicating net $I_{NS-P2X7}$. Labels correspond to those in A.

RB-2 was almost fully reversed after washing out the drug for 2 min (Fig. 1A). Figure 1B shows the I-V curves of the net $I_{NS-P2X7}$ obtained by subtracting the control current from the current in the presence of ATP before (left), in the presence of (middle) and after washing out (right) RB-2. The I-V curves of the $I_{NS-P2X7}$ showed a slight inward rectification at the negative potentials.

PPADS ($100 \mu\text{M}$) and suramin ($100 \mu\text{M}$) were tested using the same protocol as that for RB-2 and the results are shown in Figs. 2 and 3, respectively. These two antagonists also inhibited the $I_{NS-P2X7}$ and the inhibition was also completely reversed after washing out the drugs for 1 min.

Concentration-inhibition curves for the three antagonists were plotted by measuring the net $I_{NS-P2X7}$ at -100 mV (Fig. 4). The inhibitory effects of RB-2, PPADS and suramin were concentration-dependent with IC_{50} (geometric means with 95% confidence intervals) values of 4.3 (3.0–5.9), 53 (25–81) and 40 (26–60) μM , respectively. The data with RB-2, PPADS and suramin could be fit with Hill coefficients of 0.76, 1.8 and 2.4, respectively.

Effect of KN-04 on $I_{NS-P2X7}$

A Ca^{2+} -calmodulin-dependent protein kinase II inhibitor, KN-62, and its inactive analogue, KN-04, in nanomolar concentrations inhibit human P2X_7 receptor-mediated res-

ponses (20, 21). In NG108-15 cells, the $I_{NS-P2X7}$ was little affected by $1 \mu\text{M}$ KN-04, which totally inhibits the human P2X_7 receptor-mediated effect (Fig. 5). Even at $10 \mu\text{M}$, KN-04 only decreased $I_{NS-P2X7}$ to $61.3 \pm 9.5\%$ ($n = 4$) of the control value. The inhibition was reversible, as the current almost fully recovered after washing out KN-04 for 1 min.

Effect of oxidized-ATP on $I_{NS-P2X7}$

Oxidized-ATP is an irreversible inhibitor of the P2X_7 receptor in human lymphocytes (22) and of the cloned expressed human P2X_7 receptor (9). We incubated NG108-15 cells with $300 \mu\text{M}$ oxidized-ATP for 120 min, and compared the $I_{NS-P2X7}$ densities between oxidized-ATP-treated and non-treated cells. When $I_{NS-P2X7}$ was induced by ATP concentrations between 0.5 and 5 mM, no difference was found between the current in the oxidized-ATP-treated cells and that in non-treated cells (Fig. 6). This indicates that oxidized-ATP does not inhibit the P2X_7 receptor in NG108-15 cells.

Effect of prolonged ATP application on P2X_7 receptors

The inhibitory effects of oxidized-ATP on the P2X_7 receptor have been demonstrated with ATP-induced cell lysis and pore formation (23, 27) but not with the membrane current. The failure of oxidized-ATP to inhibit the




Fig. 2. Effect of PPADS on the $I_{NS-P2X7}$. A: Typical chart recordings (upper panels) and I-V curves (lower panels) of $I_{NS-P2X7}$ before (left), in the presence of (middle) and after washing out (right) PPADS. ATP was applied during the period shown by the horizontal bars. PPADS (100 μ M) was applied 30 s before ATP application. B: Difference I-V curves obtained by subtracting the control from the maximal current response to ATP at each trace in A.




Fig. 3. Effect of suramin on the $I_{NS-P2X7}$. A: Typical chart recordings (upper panels) and I-V curves (lower panels) of $I_{NS-P2X7}$ before (left), in the presence of (middle) and after washing out (right) suramin. ATP was applied during the period shown by the horizontal bars. Suramin (100 μ M) was applied 30 s before ATP application. B: Difference I-V curves obtained by subtracting the control from the maximal current response to ATP at each trace in A.

ATP-induced current in NG108-15 cells suggested that the pore-forming ability of P2X₇ receptor in these cells are different from that in other cells. Therefore, using the

whole cell clamp, we investigated whether P2X₇ receptor activation induces pore formation in NG108-15 cells. Figure 7A shows the current activated by 3 mM ATP




Fig. 4. Concentration-inhibition relationships of RB-2, PPADS and suramin. $I_{NS-P2X7}$ magnitude was measured at -100 mV. $I_{NS-P2X7S}$ in the presence of inhibitors are expressed as % of the control in the absence of the inhibitors. Each point represents the mean \pm S.E.M. from 3 to 7 cells.




Fig. 5. Effects of 1 and 10 μ M KN-04 on $I_{NS-P2X7}$. Current amplitudes were measured at -100 mV. Each column indicates the mean \pm S.E.M. from 4 cells. * $P < 0.01$ compared with the control by the Dunnett's test.

applied for 5 min. During this continuous superfusion of ATP, the current did not increase and its reversal potential did not change in Tyrode solution containing 140 mM Na^+ (Fig. 7: B and C). Figure 7D shows a similar experiment in which the external solution was switched from one containing 140 mM Na^+ to one containing 140 mM NMDG about 30 s after starting the application of ATP. Upon substituting Na^+ with NMDG, the current magnitude suddenly decreased and the reversal potential shifted from 5 mV to -55 mV (Fig. 7E). The decreased current remained almost the same during the following 6 min of ATP superfusion in the NMDG solution. When the external solution was changed from one containing NMDG back to one containing Na^+ in the presence of ATP, the current magni-




Fig. 6. Effect of oxidized-ATP on the $I_{NS-P2X7}$. The $I_{NS-P2X7}$ density was measured at -100 mV in untreated cells and cells treated with oxidized-ATP. Each symbol represents the mean \pm S.E.M. from 4 control and 5 oxidized-ATP treated cells.

tude and the reversal potential were restored nearly to their initial value. These results indicate that prolonged stimulation with ATP does not promote the $P2X_7$ receptors to form pores large enough for the permeation of NMDG and Na equally into NG108-15 cells.

We examined whether Yo-Pro-1 uptake occurs during $P2X_7$ receptor stimulation in NG108-15 cells. ATP (1 mM) did not increase Yo-Pro-1 fluorescence during a 4 min-exposure (Fig. 8). In contrast, membrane disruption by digitonin (50 μ g/ml) markedly increased Yo-Pro-1 fluorescence (Fig. 8). Yo-Pro-1 or ethidium bromide uptake through the $P2X_7$ receptors is reported to be facilitated at low concentrations of external divalent cations (9, 29). However, in our experiment, even in a low divalent cation-medium (Mg^{2+} -free and 0.18 mM $CaCl_2$), ATP was unable to stimulate the Yo-Pro-1 uptake in NG108-15 cells (data not shown). This result also indicates that large pores were not formed in NG108-15 cells by prolonged application of ATP.

DISCUSSION

$P2X_7$ receptor stimulation has been reported to lead to two types of molecular responses, namely the opening of intrinsic nonselective cation channels and the formation of large pores, resulting in diverse cellular reactions such as Ca^{2+} influx, uptake of large molecules, cytokine release, activation of phospholipase D, shedding L-selectin from the cell surface, and cell lysis (23, 27, 30, 31). Our results demonstrated that the ATP-induced current through the $P2X_7$ receptor activation in NG108-15 cells had unique antagonist sensitivity compared with those in other cell types, and that prolonged stimulation of the $P2X_7$ receptor did not induce pore formation in NG108-15 cells.




Fig. 7. Effects of prolonged application of ATP on the $I_{NS-P2X7}$ with Na^+ or NMDG in the external solutions. A: Typical chart recording of the $I_{NS-P2X7}$ induced by 3 mM ATP in Tyrode solution containing 140 mM Na^+ . The horizontal bars above indicate when ATP was present. B: I-V curves before ATP application (a), maximum current induced by ATP (b), after 3 min (c) and 5 min (d) as indicated in A. C: Difference I-V curves of b-a, c-a and d-a in B. D: Typical chart recording of the $I_{NS-P2X7}$ induced by 3 mM ATP in Tyrode solution containing 140 mM Na^+ or 140 mM NMDG. The horizontal bars above indicate when ATP, Na^+ and NMDG were present. E: I-V curves before ATP application (a), maximum current induced by ATP (b), just after changing to NMDG (c), after 5 min in NMDG (d) and after returning to Na^+ (e) as indicated in D.

In NG108-15 cells, RB-2 was more potent than PPADS and suramin. The IC_{50} values of RB-2, PPADS and suramin were 4.3, 53 and 40 μ M, respectively. This order of potency is different from that with human P2X₇ receptors because PPADS is more potent ($IC_{50} = 1 \mu$ M) than suramin ($IC_{50} = 70 \mu$ M) in inhibiting the human P2X₇ receptor current in HEK-293 cells (18). The $I_{NS-P2X7}$ from NTW8 microglial cells is more sensitive to RB-2 than PPADS (29), which is similar to our results with NG108-15 cells. Thus, the difference noted above may be due to the species differences because the P2X₇ receptors in both NG108-15 and NTW8 cells are from mouse origin (26). The Hill




Fig. 8. Effect of ATP on Yo-Pro-1 fluorescence. ATP (1 mM) and digitonin (50 μ g/ml) were added as indicated (arrows) while Yo-Pro-1 uptake in NG108-15 cells was measured by fluorescence. No uptake was detected with ATP, but significant fluorescence was detected with digitonin.

coefficient of RB-2, is close to 1, while those of PPADS and suramin are greater than 1, indicating that one molecule of RB-2 and more than one molecule of PPADS and suramin may be involved in the inhibition of one functional P2X₇ receptor.

Chessell et al. (29) observed no effect of 100 μ M suramin on the rising phase of the current in mouse NTW8 cells when they applied ATP for only 0.5 s with their quick solution change method. In contrast, we observed that suramin considerably diminished the initial rising state of the $I_{NS-P2X7}$ and greatly inhibited the maximal current 10–20 s after ATP application. It is likely that the P2X₇ receptors differ in different cell lines even though the cell lines originated from the same species. However the possibility that the discrepancy is due to the different methods of ATP application can not be excluded.

Unlike other P2X receptor subtypes, several selective antagonists have been found for the P2X₇ receptors. The calmodulin kinase II inhibitor KN-62 and its ineffective analogue KN-04 inhibit the human lymphocyte P2X₇-receptor-mediated Ba^{2+} influx and ethidium uptake at nanomolar concentrations (20), but did not affect the responses mediated through the rat P2X₇ receptors (30). Human and rat P2X₇ receptors have 80% homology in amino acid sequences (21). Introduction of the first 335 amino acids of the human P2X₇ receptor to the rat P2X₇ receptor conferred KN-62 sensitivity (21), suggesting that the drug interacts with residues in the amino-terminal half of the human P2X₇ receptor which contains the large extracellular loop. In NG108-15 cells, KN-04 at 1 μ M had no effect and it only partly inhibited the $I_{NS-P2X7}$ at 10 μ M. Similar weak inhibition was found for KN-62. These results can not be explained by species differences, because KN-62 inhibits both native and recombinant mouse P2X₇ receptors from

the NTW8 microglial cell line with IC_{50} s of 1.17 μ M and 180 nM, respectively (31). A significant difference was also obtained with oxidized-ATP, another selective blocker of human, rat and mouse P2X₇ receptors (22, 23, 27, 32). Oxidized-ATP had no effect on the $I_{NS-P2X7}$ in NG108-15 cells. This also cannot be explained by species differences. However, it should be noted that the effects of KN-62 (33) and oxidized-ATP (27) on mouse P2X₇ receptors were demonstrated with ATP-induced pore formation, but not with the activation by ATP of non-selective cation channels. Several lines of evidence suggest that the induction of non-selective cationic current does not always correlate with pore formation. In recombinant human P2X₇ receptors, PPADS inhibits ATP-induced pore formation with an IC_{50} of 15 nM, while inhibition of the current requires a 100-fold higher concentration of PPADS (18). Calmidazolium inhibits the rat P2X₇ receptor current without affecting pore formation (34). In addition, the rat P2X₇ receptor expressed in *Xenopus* oocytes does not form a pore (35). Therefore, channel activation and pore formation appear to be separate events that are affected differently by KN-compounds and oxidized-ATP.

With respect to the P2X₇ receptor pore formation, our results suggest that prolonged stimulation of the P2X₇ receptor did not induce pore formation in NG108-15 cells. The P2X₇ receptor in NG108-15 cells is less permeable to NMDG than to Na⁺ (7). The rat P2X₇ receptor in macrophages, which has a marked pore forming activity, is equally permeable to NMDG and Na⁺ (35). In addition, Khakh et al. (36) and Virginio et al. (37) showed that prolonged activation of P2X₂ and P2X₄ receptors progressively increased their permeability to NMDG and proposed a pore dilatation property for these P2X receptor subtypes. We did not observe such a change in the permeability to NMDG in NG108-15 cells during the application of 3 mM ATP for 6 min. Pore formation was facilitated at low concentrations of divalent cations, but also occurred in normal divalent cations at 32°C in mouse NTW8 microglial cells (29). Yo-Pro-1 uptake was observed at 1 mM CaCl₂ at 37°C in the mouse P2X₇ receptor in HEK-293 cells and in the native NTW8 cells (33). In this study, we showed that prolonged stimulation of the P2X₇ receptor in NG108-15 cells did not increase Yo-Pro-1 uptake even in a low divalent cations-medium. Thus, we conclude that the mouse P2X₇ receptors in NG108-15 cells do not form large pores. These results might be related to the lack of effects of KN-04 and oxidized-ATP in NG108-15 cells.

An alternative explanation for the different sensitivities to antagonists and lack of pore formation in NG108-15 cells would be that some other cellular protein is either deficient or present in these cells that alters the properties of the P2X₇ channels. Another possibility is that the P2X₇ receptor may be heteromeric. Heteromeric P2X receptors

have been demonstrated as combinations of P2X₂ and P2X₃ (38, 39), P2X₁ and P2X₅ (40), and P2X₄ and P2X₆ receptor subtypes (41). In NG108-15 cells, considerable levels of mRNAs for P2X₃ and P2X₄ receptors were detected (I. Matsuoka, unpublished data). However, we could not measure any membrane current at lower concentrations of ATP, which is an indication that homomeric P2X₃ or P2X₄ receptors are not expressed in these cells. The interaction between these P2X receptor subtypes and the P2X₇ receptor would be an important subject for future study.

Acknowledgments

We thank Professor T. Shimizu, Department of Physiology, Fukushima Medical University School of Medicine, for permitting us to use the patch-clamp apparatus in his department. We also thank Ms S. Sato and Dr. T. Ono for their technical assistance. This work was supported by the Japan Health Science Foundation (21279), the Smoking Research Foundation, and Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (11770047, 11670096, 11357020).

REFERENCES

- 1 Valera S, Hussy N, Evans RJ, Adami N, North RA, Surprenant A and Buell G: A new class of ligand-gated ion channel defined by P2x receptor for extracellular ATP. *Nature* **371**, 516–519 (1994)
- 2 Brake AJ, Wagenbach MJ and Julius D: New structural motif for ligand-gated ion channels defined by an ionotropic ATP receptor. *Nature* **371**, 519–523 (1994)
- 3 Kimura J, Kaiho H and Matsuoka I: P2Z/P2X₇ receptor (a review). *Recent Res Dev Neurochem* **2**, 241–246 (1999)
- 4 Nihei OK, Savino W and Alves LA: Procedures to characterize and study P2Z/P2X₇ purinoceptor: flow cytometry as a promising practical, reliable tool. *Mem Inst Oswaldo Cruz* **95**, 415–428 (2000)
- 5 North RA and Barnard EA: Nucleotide receptors. *Curr Opin Neurobiol* **7**, 346–357 (1997)
- 6 Cockcroft S and Gomperts BD: The ATP₄-receptor of rat mast cells. *Biochem J* **188**, 789–798 (1980)
- 7 Kaiho H, Kimura J, Matsuoka I, Kumasaka T and Nakanishi H: ATP-activated nonselective cation current in NG108-15 cells. *J Neurochem* **67**, 398–406 (1996)
- 8 Burnstock G: The past, present and future of purine nucleotides as signalling molecules. *Neuropharmacology* **36**, 1127–1139 (1997)
- 9 Surprenant A, Rassendren F, Kawashima E, North RA and Buell G: The cytolitic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X₇). *Science* **272**, 735–738 (1996)
- 10 Rassendren F, Buell GN, Virginio C, Collo G, North RA and Surprenant A: The permeabilizing ATP receptor, P2X₇. Cloning and expression of a human cDNA. *J Biol Chem* **272**, 5482–5486 (1997)
- 11 Chiozzi P, Murgia M, Falzoni S, Ferrari D and Di Virgilio F: Role of the purinergic P2Z receptor in spontaneous cell death in J774 macrophage cultures. *Biochem Biophys Res Commun* **218**, 176–181 (1996)
- 12 Di Virgilio F: The P2Z purinoceptor: an intriguing role in immunity, inflammation and cell death. *Immunol Today* **16**, 524–528

- (1995)
- 13 Matsuoka I, Zhou Q, Ishimoto H and Nakanishi H: Extracellular ATP stimulates adenylyl cyclase and phospholipase C through distinct purinoceptors in NG108-15 cells. *Mol Pharmacol* **47**, 855 – 862 (1995)
 - 14 Kaiho H, Matsuoka I, Kimura J and Nakanishi H: Identification of P2X₇ (P2Z) receptor in N18TG-2 cells and NG108-15 cells. *J Neurochem* **70**, 951 – 957 (1998)
 - 15 Chueh SH and Kao LS: Extracellular ATP stimulates calcium influx in neuroblastoma × glioma hybrid NG108-15 cells. *J Neurochem* **61**, 1782 – 1788 (1993)
 - 16 Chueh SH, Hsu LS and Song SL: Two distinct ATP signaling mechanisms in differentiated neuroblastoma × glioma hybrid NG108-15 cells. *Mol Pharmacol* **45**, 532 – 539 (1994)
 - 17 Wiley JS, Chen R and Jamieson GP: The ATP⁴⁺ receptor-operated channel (P2Z class) of human lymphocytes allows Ba²⁺ and ethidium⁺ uptake: inhibition of fluxes by suramin. *Arch Biochem Biophys* **305**, 54 – 60 (1993)
 - 18 Chessell IP, Michel AD and Humphrey PP: Effects of antagonists at the human recombinant P2X₇ receptor. *Br J Pharmacol* **124**, 1314 – 1320 (1998)
 - 19 McMillian MK, Soltoff SP, Cantley LC, Rudel R and Talamo BR: Two distinct cytosolic calcium responses to extracellular ATP in rat parotid acinar cells. *Br J Pharmacol* **108**, 453 – 461 (1993)
 - 20 Gargett CE and Wiley JS: The isoquinoline derivative KN-62 a potent antagonist of the P2Z-receptor of human lymphocytes. *Br J Pharmacol* **120**, 1483 – 1490 (1997)
 - 21 Humphreys BD, Virginio C, Surprenant A, Rice J and Dubyak GR: Isoquinolines as antagonists of the P2X₇ nucleotide receptor: high selectivity for the human versus rat receptor homologues. *Mol Pharmacol* **54**, 22 – 32 (1998)
 - 22 Wiley JS, Chen JR, Snook MB and Jamieson GP: The P2Z-purinoceptor of human lymphocytes: actions of nucleotide agonists and irreversible inhibition by oxidized ATP. *Br J Pharmacol* **112**, 946 – 950 (1994)
 - 23 Zoetewij JP, van de Water B, de Bont HJ and Nagelkerke JF: The role of a purinergic P2z receptor in calcium-dependent cell killing of isolated rat hepatocytes by extracellular adenosine triphosphate. *Hepatology* **23**, 858 – 865 (1996)
 - 24 Ohkubo S, Kimura J and Matsuoka I: Correlation between adenine nucleotide-induced cyclic AMP elevation and extracellular adenosine formation in NG108-15 cells. *Jpn J Pharmacol* **84**, 325 – 333 (2000)
 - 25 Hamill OP, Marty A, Neher E, Sakmann B and Sigworth FJ: Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. *Pflugers Arch* **391**, 85 – 100 (1981)
 - 26 Kaiho H, Kimura J, Matsuoka I and Nakanishi H: Effects of anions on ATP-activated nonselective cation current in NG108-15 cells. *J Neurophysiol* **77**, 2717 – 2722 (1997)
 - 27 Murgia M, Hanau S, Pizzo P, Ripa M and Di Virgilio F: Oxidized ATP. An irreversible inhibitor of the macrophage purinergic P2Z receptor. *J Biol Chem* **268**, 8199 – 8203 (1993)
 - 28 Hickman SE, el Khoury J, Greenberg S, Schieren I and Silverstein SC: P2Z adenosine triphosphate receptor activity in cultured human monocyte-derived macrophages. *Blood* **84**, 2452 – 2456 (1994)
 - 29 Chessell IP, Michel AD and Humphrey PP: Properties of the pore-forming P2X₇ purinoceptor in mouse NTW8 microglial cells. *Br J Pharmacol* **121**, 1429 – 1437 (1997)
 - 30 Humphreys BD and Dubyak GR: Induction of the P2z/P2X₇ nucleotide receptor and associated phospholipase D activity by lipopolysaccharide and IFN-gamma in the human THP-1 monocytic cell line. *J Immunol* **157**, 5627 – 5637 (1996)
 - 31 Chen JR, Gu BJ, Dao LP, Bradley CJ, Mulligan SP and Wiley JS: Transendothelial migration of lymphocytes in chronic lymphocytic leukaemia is impaired and involved down-regulation of both L-selectin and CD23. *Br J Haematol* **105**, 181 – 189 (1999)
 - 32 Falzoni S, Munerati M, Ferrari D, Spisani S, Moretti S and Di Virgilio F: The purinergic P2Z receptor of human macrophage cells. Characterization and possible physiological role. *J Clin Invest* **95**, 1207 – 1216 (1995)
 - 33 Chessell IP, Simon J, Hibell AD, Michel AD, Barnard EA and Humphrey PP: Cloning and functional characterisation of the mouse P2X₇ receptor. *FEBS Lett* **439**, 26 – 30 (1998)
 - 34 Virginio C, Church D, North RA and Surprenant A: Effects of divalent cations, protons and calmidazolium at the rat P2X₇ receptor. *Neuropharmacology* **36**, 1285 – 1294 (1997)
 - 35 Nuttle LC and Dubyak GR: Differential activation of cation channels and non-selective pores by macrophage P2z purinergic receptors expressed in *Xenopus* oocytes. *J Biol Chem* **269**, 13988 – 13996 (1994)
 - 36 Khakh BS, Bao XR, Labarca C and Lester HA: Neuronal P2X transmitter-gated cation channels change their ion selectivity in seconds. *Nat Neurosci* **2**, 322 – 330 (1999)
 - 37 Virginio C, MacKenzie A, Rassendren FA, North RA and Surprenant A: Pore dilation of neuronal P2X receptor channels. *Nat Neurosci* **2**, 315 – 321 (1999)
 - 38 Radford KM, Virginio C, Surprenant A, North RA and Kawashima E: Baculovirus expression provides direct evidence for heteromeric assembly of P2X₂ and P2X₃ receptors. *J Neurosci* **17**, 6529 – 6533 (1997)
 - 39 Virginio C, North RA and Surprenant A: Calcium permeability and block at homomeric and heteromeric P2X₂ and P2X₃ receptors, and P2X receptors in rat nodose neurones. *J Physiol (Lond)* **510**, 27 – 35 (1998)
 - 40 Torres GE, Haines WR, Egan TM and Voigt MM: Co-expression of P2X₁ and P2X₅ receptor subunits reveals a novel ATP-gated ion channel. *Mol Pharmacol* **54**, 989 – 993 (1998)
 - 41 Le KT, Babinski K and Seguela P: Central P2X₄ and P2X₆ channel subunits coassemble into a novel heteromeric ATP receptor. *J Neurosci* **18**, 7152 – 7159 (1998)